A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy

Value in Health

Volumn 11, Issue 7, 2008, Pages 1144-1153

  Kauf, Teresa L ^a,f   Roskell, Neil ^b   Shearer, Arran ^c   Gazzard, Brian ^d   Mauskopf, Josephine ^b   Davis, E Anne ^e   Nimsch, Christopher ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

^f Department of Pharmaceutical Sciences and Experimental Therapeutics   (United States)

Author keywords

AIDS; Health state utility; Methods; Preference based measures; SF 36

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; AGED; ANEMIA; ARTHRITIS; ARTICLE; BONE PAIN; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE UTILIZATION; HEALTH STATUS; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYALGIA; NAUSEA; NEURALGIA; NIGHTMARE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SEX RATIO; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 53749095731     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00326.x     Document Type: Article

References (47)

1. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care 1995 33 : AS173 82.
2. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med 1999 131 : 194 8.
3. Wu AW, Mathews WC, Brysk LT, et al. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1990 3 : 683 90.
4. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997 16 : 54 62.
5. Freedberg KA, Scharfstein JA, Seage GR III., et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998 279 : 130 6.
6. Schackman BR, Goldie SJ, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002 22 : 27 38.
7. Mrus JM, Yi MS, Freedberg KA, et al. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making 2003 23 : 414 21.
8. Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care 1998 4 : 1004 12.
9. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001 344 : 824 31.
10. Chancellor JV, Hill AM, Sabin CA, et al. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997 12 : 54 66.
11. Mauskopf J, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005 39 : 562 9.
12. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004 5 : 294 304.
13. Trueman P, Youle M, Sabin CA, et al. The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom. HIV Clin Trials 2000 1 : 27 35.
14. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003 115 : 632 41.
15. Paltiel AD, Scharfstein JA, Seage GR III., et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998 18 (Suppl. S93 105.
16. Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 2005 39 : 69 77.
17. Schackman BR, Goldie SJ, Weinstein MC, et al. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health 2001 91 : 1456 63.
18. Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002 162 : 2478 86.
19. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 2002 22 : 475 81.
20. Badia X, Monserrat S, Roset M, Herdman M. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Qual Life Res 1999 8 : 303 10.
21. Goossens ME, Vlaeyen JW, Rutten-van Molken MP, van der Linden SM. Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 1999 80 : 365 75.
22. Stavem K. Quality of life in epilepsy: comparison of four preference measures. Epilepsy Res 1998 29 : 201 9.
23. Hornberger J, Kilby JM, Wintfeld N, Green J. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Res Hum Retroviruses 2006 22 : 240 7.
24. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976 10 : 128 36.
25. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996 34 : 702 22.
26. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 5, 2005. Available from: http://www.aidsinfo.nih.gov/guidelines/ [Accessed April 12, 2006].
27. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003 348 : 2175 85.
28. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003 348 : 2186 95.
29. GlaxoSmithKline Inc. GlaxoSmithKline Clinical Trial Register. 2006. Available from: http://ctr.gsk.co.uk/welcome.asp [Accessed July 26, 2006].
30. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006 7 : 85 98.
31. Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005 39 : 257 64.
32. Sosa N, Hill-Zabala C, DeJesus E, et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr 2005 40 : 422 7.
33. Ware JE Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
34. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 92.
35. Centers for Disease Control and Prevention. Risk Factors for HIV Transmission. 2007. Available from: http://www.cdc.gov/hiv/topics/basic/index. htm#risk [Accessed September 7, 2007].
36. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med 2001 161 : 1281 8.
37. Liu C, Johnson L, Ostrow D, et al. Predictors for lower quality of life in the HAART era among HIV-infected men. J Acquir Immune Defic Syndr 2006 42 : 470 7.
38. Protopopescu C, Marcellin F, Spire B, et al. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual Life Res 2007 16 : 577 91.
39. Wu AW, Huang IC, Gifford AL, et al. Creating a crosswalk to estimate AIDS Clinical Trials Group quality of life scores in a nationally representative sample of persons in care for HIV in the United States. HIV Clin Trials 2005 6 : 147 57.
40. Call SA, Klapow JC, Stewart KE, et al. Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res 2000 9 : 977 85.
41. Burgoyne RW, Rourke SB, Behrens DM, Salit IE. Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile. AIDS Behav 2004 8 : 151 63.
42. Gill CJ, Griffith JL, Jacobson D, et al. Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life. J Acquir Immune Defic Syndr 2002 30 : 485 92.
43. Miners AH, Sabin CA, Mocroft A, et al. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clin Trials 2001 2 : 484 92.
44. Murri R, Fantoni M, Del Borgo C, et al. Determinants of health-related quality of life in HIV-infected patients. AIDS Care 2003 15 : 581 90.
45. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992 41 : 1 19.
46. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003 1 : 4.
47. Mrus JM, Williams PL, Tsevat J, et al. Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res 2005 14 : 479 91.